Follow-up and non-urgent information for quality defects

Sponsor's report on the maintenance of the designation criteria at the time of marketing authorisation for a designated orphan-medicinal-product

Human medicines European public assessment report (EPAR): Fabrazyme, agalsidase beta, Date of authorisation: 03/08/2001, Revision: 37, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 17 October 2024, 13:30 (CEST) to 17 October 2024, 17:30 (CEST)

ICH guideline E11A on pediatric extrapolation - Scientific guideline

ICH guideline E11A on pediatric extrapolation Step 5

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Jevtana, cabazitaxel, Date of authorisation: 17/03/2011, Revision: 24, Status: Authorised

Concept paper on revision of the Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling

Human medicines European public assessment report (EPAR): Pramipexole Teva, pramipexole, Date of authorisation: 18/12/2008, Revision: 24, Status: Authorised